BP's in past decades have continually worked to strategize launches with pricing a major driver along with other considerations. This includes either overlapping submissions at strategic review points or using one approval to smooth the path to another, depending upon which markets are targeted. Small bio's tend to wait to submit to add'l countries until they get their first approval more often I think because they tend to receive more questions in application reviews. The USA has always been the most popular first approval, at least for USA based companies, since it is the largest pharma market, the highest priced pharma market and the market where USA based companies are established and knowledgeable. Read the generalized brief article below and think for a minute why it would be so important to launch in the USA first if the UK has become a more partnering environment for new innovative drugs and is seen as less corrupted or we may say less aligned with the BP's in the industry.
Market Data 
Markets 
AI
